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Abstract  24 
Background: It is uncertain whether improvements in primary care high-risk prescribing seen in research trials can 25 
be realised in the ‘real-world’ setting. 26 
 Aim: To evaluate the impact of a one-year system-wide phase 4 prescribing safety improvement initiative. 27 
Design and Setting: Interrupted time-series analysis of targeted high-risk prescribing in all 56 general practices in 28 
NHS Forth Valley, Scotland (in 2013/14: non-steroidal anti-inflammatory drugs (NSAIDs) in older people, the triple 29 
whammy and NSAIDs with oral anticoagulants; in 2014/2015: antipsychotics in older people).   30 
Method: Primary analysis used segmented regression analysis to estimate impact at the end of the intervention, and 31 
twelve months later. Secondary analysis used difference-in-difference methods to compare Forth Valley changes 32 
with those in NHS Greater Glasgow and Clyde (GGC).  33 
Results: In primary analysis, downward trends for all three NSAID measures before the intervention significantly 34 
steepened following implementation. At the end of the intervention period, 1,221 fewer patients than expected 35 
were prescribed a high-risk NSAID. In contrast, antipsychotic prescribing in older people increased slowly over time 36 
with no intervention-associated change.  In secondary analysis, reductions at the end of the intervention period in all 37 
three NSAID measures were significantly greater in Forth Valley than in GGC, but only significantly greater for two of 38 
these measures twelve months after the intervention finished. 39 
Conclusion: There were substantial and sustained reductions in high-risk prescribing of NSAIDs, although with some 40 
waning of effect twelve months after the intervention ceased. The same intervention had no effect on antipsychotic 41 
prescribing in older people. 42 
 43 
Keywords: quality improvement; phase 4 complex intervention; high-risk prescribing; non-steroidal anti-44 
inflammatory drugs (NSAIDs); antipsychotic drugs; General Practice, interrupted time series analysis; administrative 45 
data   46 
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How this fits in 47 
There is good evidence from phase 3 cluster-randomised trials that a number of interventions 
reduce high-risk prescribing in primary care, but whether similar improvements can be realised in 
the ‘real-world’ setting is less clear.  
A system-wide quality improvement intervention combining education, feedback, support to identify 
patients to review, and small financial incentives resulted in large reductions in high-risk prescribing 
of non-steroidal anti-inflammatory drugs (NSAIDs) of a similar magnitude to those seen in phase 3 
trials.  
Phase 3 trials rarely examine what happens after the intervention ends, but in this study there was 
evidence that the effect on high-risk NSAID prescribing waned somewhat in the year after the 
intervention ended, highlighting the need for healthcare improvement to monitor impact longer 
term and consider interventions to sustain benefit. 
There was no effect of the same intervention on high-risk prescribing of oral antipsychotics, 
highlighting that interventions may have differential effectiveness depending on the wider context 
of prescribing (in this case, NSAID prescribing is ‘owned’ by general practitioners but antipsychotic 
prescribing is usually specialist initiated).   
  48 
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Introduction 49 
High-risk prescribing is common in primary care1, 2 although it is not always inappropriate since expected benefit can 50 
outweigh expected harm in individual patients. Drugs commonly implicated in preventable adverse drug events 51 
(ADEs) resulting in hospital admissions include non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin which are 52 
responsible for 30% of ADE-related hospital admissions, due to bleeding, stroke, and renal injury.3 Similar to primary 53 
care organisations elsewhere, Health Boards in Scotland use a variety of means to try to influence primary care 54 
prescribing, including education and feedback, pharmacist-support, and small financial incentives.4, 5 Historically,  the 55 
focus of most of this work has been on controlling prescribing costs,6 but the growing availability of better 56 
prescribing data opens up new opportunities to target quality and safety such as the NHS Forth Valley intervention 57 
to improve primary care prescribing safety (Box 1). 58 
A range of prescribing safety indicators have been developed,7-9 and interventions to improve subsets of them 59 
evaluated in phase 3 cluster-randomised trials in primary care.10-13 The PINCER trial evaluated practitioner education, 60 
informatics tools to identify relevant patients, and intensive pharmacist support to review patients and improve 61 
prescribing systems.11 For the three primary high-risk prescribing outcome indicators (non-selective non-steroidal 62 
anti-inflammatory drugs (NSAIDs) prescribed to those with a history of peptic ulcer without co-prescription of a 63 
proton-pump inhibitor; β blockers prescribed to those with a history of asthma; long-term prescription of 64 
angiotensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment of 65 
urea and electrolytes in the preceding 15 months) there was a reduction in the odds of each of of 27-49% at 6 66 
months, which diminished to 9-37% by 12 months.  The DQIP trial evaluated education, informatics to support 67 
patient identification, and financial incentives for patient review.12 There was a 41% reduction in the odds of the 68 
composite measure of targeted high-risk prescribing at one year, sustained in the following year. The lower-intensity 69 
EFIPPS intervention had a 14% reduction in the odds of six measures of high-risk NSAID and antipsychotic prescribing 70 
after five rounds of quarterly feedback.13 However, whether these improvements can be replicated in everyday 71 
practice is uncertain. The UK Medical Research Council recommends phase 4 evaluation to “determine whether 72 
others can reliably replicate your intervention and results in uncontrolled settings over the long term”10 since 73 
“effects are likely to be smaller and more variable once the intervention becomes implemented more widely, and … 74 
long-term follow-up may be needed to determine whether short-term changes persist.”.14 The aim of this phase 4 75 
study is to evaluate the impact of a complex, whole system real-world intervention to improve prescribing safety 76 
implemented in all practices in a Scottish Health Board region with a population ~300,000, including whether impact 77 
was sustained post-intervention.   78 
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Methods 79 
The overall design is segmented regression analysis of interrupted time series data from a Scottish Health Board 80 
implementing the intervention, and a comparator Scottish Health Board that did not. There are ~300,000 registered 81 
patients in the intervention Health Board (NHS Forth Valley) and ~1,200,000 registered patients in the neighbouring 82 
comparator Health Board (NHS Greater Glasgow and Clyde [GGC]). 83 
Data Source 84 
Data on prescriptions dispensed by community pharmacies between April 2009 and September 2015 were extracted 85 
from the NHS Scotland Prescribing Information System (PIS). 94.7% of dispensed prescriptions in NHS Forth Valley 86 
and 94.5% in NHS GGC have an associated unique patient identifier, allowing the construction of patient-level 87 
prescribing histories and the identification of co-prescribing in individuals.  88 
Interventions and outcomes  89 
In financial year 2013/14, NHS Forth Valley implemented a prescribing improvement intervention targeting three 90 
high-risk NSAID prescribing measures as part of their annual Whole System Working (WSW) primary care 91 
improvement programme (box 1). The WSW intervention included education, feedback, searches and pharmacist 92 
support to identify relevant patients from electronic health records, and financial incentives for practices to report 93 
any changes in the high-risk prescribing rates to the Health Board at year-end. In 2014/2015, a new measure 94 
(antipsychotic use in people aged 75 years and over) replaced the NSAID measures targeted in the previous year. The 95 
prescribing measures used in the intervention and evaluation were ones used in the EFIPPS trial 13 (that neither Forth 96 
Valley nor GGC participated in), and are shown in table 1. 97 
Over the same period, NHS Greater Glasgow and Clyde (GGC) chose to focus on other areas of prescribing 98 
improvement, including medication review in older people with polypharmacy at risk of re-admission to hospital. 99 
High risk prescribing of NSAIDs and oral antipsychotics was included in the medication review guidance but there 100 
was no specific targeting of the measures used in Forth Valley.15  Within each Health Board more than 95% of 101 
practices participated in these activities.  102 
Statistical analysis 103 
The primary analysis used segmented regression of interrupted time-series (ITS) data to examine the impact of the 104 
implementation and withdrawal after one year of the WSW intervention in Forth Valley. The intervention period 105 
started at the beginning of quarter 2 (April) of the relevant year, and finished at the end of quarter 1 of the next year 106 
(March) (table 1). For each measure in Forth Valley, the trend before each interruption, step-changes immediately 107 
after intervention period start and end, and changes in trend following the start and end of the intervention period 108 
were estimated.  Model estimates were used to calculate the intervention effect (by subtracting the observed value 109 
from the predicted value if prior trends had continued) at the end of the 12 month intervention period, and at 12 110 
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months after the intervention period ended.16 17  The overall intervention effect of the three measures of high-risk 111 
NSAID prescribing was estimated using a composite of all three that accounted for some patients having multiple risk 112 
factors. Secondary analyses compared changes in NHS Forth Valley with changes in the same prescribing measures in 113 
the same period in NHS GGC. For this analysis, a segmented regression model was fitted for the difference between 114 
rates in the two Health Boards (Forth Valley minus GGC), allowing estimation of the difference-in-differences of 115 
change in Forth Valley relative to change in GGC (appendix A).18 116 
For the three NSAID measures there were 16 quarterly time-points before the intervention start, four during the 117 
intervention period, and eight after the intervention period. For the antipsychotics in older people measure, there 118 
were 20 quarterly time-points before, four during and four after the intervention period.  Modelling accounted for 119 
autocorrelation by using the Cumby-Huizinga general test and fitting lag terms to models as required.  Newey-West 120 
standard errors were estimated to account for autocorrelation and possible heteroscedasticity.19  Statistical analysis 121 
was undertaken using Stata v13.1 (Statacorp, College Station, Texas).   122 
Results  123 
NHS Forth Valley NSAIDs 2013-14 124 
All three NSAID measures had a statistically significant downward trend before the implementation of WSW 125 
between April 2013 and March 2014. Following the implementation start at April 2013 there was no immediate 126 
change in the rate of prescribing for the triple whammy and NSAIDs in older people measures, but the existing 127 
downward trends significantly steepened (table 2; figure 1). For NSAIDs with OAC, there was a statistically significant 128 
immediate decrease in prescribing, but no significant change in trend.  At the end of the intervention period in April 129 
2014, there was a statistically significant immediate increase in both triple whammy and NSAID prescribing in older 130 
people, but not for NSAIDs with OAC.  After the end of the intervention period, there were statistically significant 131 
changes in trend leading either to a reversion to pre-intervention downward trends (triple whammy) or a diminished 132 
intervention effect (NSAIDs in older people and NSAIDs with OAC).  133 
Compared to rates predicted based on pre-intervention trends, the estimated relative effect at the end of the 134 
intervention period in April 2014was a 55.4% (95% CI 43.6 to 67.2) reduction for the triple whammy measure, a 135 
69.9% (95% CI 59.6 to 80.2) reduction for NSAIDs in older people, and a 55.1% (95% CI 27.0 to 83.2) reduction for 136 
NSAIDs with OAC. The relative impact 12 months after the intervention period ended in April 2015 was still 137 
substantial but somewhat smaller: reductions of 42.7% (95% CI 27.4 to 58.0), 40.1% (95% CI 26.4 to 53.8) and 27.6% 138 
(-11.4 to 66.7, not statistically significant) respectively (table 3).  139 
Pre-intervention trends in GGC were not significantly different from Forth Valley for the triple whammy and NSAIDs 140 
with OAC measures. For NSAIDs in older people there was a small but statistically significant more rapid decline in 141 
the pre-intervention trend in Forth Valley than GGC (figure 1, appendix table A1).  For the triple whammy measure, 142 
at the end of the intervention period in April 2014 there was a reduction of 34.3% (95% CI 26.4 to 42.3) relative to 143 
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GGC which diminished over the 12 months after the intervention finished in April 2015 to a reduction of 25.7% (95% 144 
CI 15.2 to 36.3) (table 3). For NSAIDs in older people, at the end of the intervention period in Apri l 2014 there was a 145 
reduction of 59.4% (95% CI 52.5 to 66.3) relative to GGC reducing to 28.6% (95% CI 18.8 to 38.3) by April 2015 (table 146 
3).  For NSAIDs with OAC at the end of the intervention period there was a reduction of 85.0% (95% CI 45.5 to 100) 147 
relative to GGC reducing to 69.0% (95% CI 27.2 to 100) by April 2015 (table 3).  148 
The total reduction in the number of patients prescribed triple whammy, NSAIDs in older people or NSAIDs with 149 
OAC, accounting for some patients having multiple risk factors, was 1,221 fewer patients than expected at the end of 150 
the intervention period at April 2014.  At April 2015, 12 months after the intervention ended, there were 751 fewer 151 
patients than expected triggering one or more of the three indicators. 152 
NHS Forth Valley antipsychotics 2014-15 153 
There was a non-significant increase in prescribing of antipsychotics in older people in Forth Valley before the 154 
intervention and no statistically significant changes immediately after the WSW intervention was introduced in April 155 
2014. The upward trend significantly steepened at the time the intervention period ended at April 2015 (although in 156 
absolute terms the change is small) (table 2; figure 2). There was no significant estimated impact at the end of the 157 
intervention period or 12 months later (table 4). 158 
GGC had a higher baseline rate than Forth Valley that was falling rather than rising. At the end of the intervention 159 
period in April 2015Forth Valley had a 11.3% (95% CI 3.6 to 18.9) reduction relative to GGC but this difference was 160 
driven by an increase in GGC (figure 2) so is unrelated to the WSW intervention. There was no statistically significant 161 
difference 12 months after the end of the intervention period in April 2016 (appendix table A1 and table 3). 162 
Discussion 163 
Summary 164 
The Whole System Working intervention implemented in all Forth Valley practices in 2013/14 led to large (>55%) 165 
reductions in the three targeted measures of high-risk NSAID prescribing at the end of the intervention period. There 166 
was evidence of a diminished intervention effect 12 months later, but reductions were still substantial.  Relative to 167 
GGC these observed reductions remained significant, increasing confidence that the intervention was effective. In 168 
contrast, the same WSW intervention in 2014/15 was not associated with any change in antipsychotic prescribing in 169 
older people.  Although there were significant ‘reductions’ in Forth Valley relative to GGC we interpret the observed 170 
‘reduction’ as being due to increased prescribing in GGC rather than due to the intervention in Forth Valley.   171 
Strengths and limitations 172 
Interrupted times series analysis (ITSA) is the most robust method available for evaluating non-randomised 173 
interventions. This analysis used population-based routine data to examine a system-wide prescribing safety 174 
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intervention using ITSA.  Secondary comparison with another Health Board (that did not implement specific 175 
improvement activity on the targeted prescribing) was consistent with the observed changes in Forth Valley being 176 
attributable to the intervention. Limitations include the risk of under-detection of high-risk prescribing because not 177 
all prescriptions have a usable unique patient identifier although we would not expect this to alter the interpretation 178 
since there was no change in this over time and no difference between the Health Boards. The assumptions of the 179 
difference-in-differences model were violated for the antipsychotics in older people measure since there were 180 
different prior trends in the two health boards, and we conclude that the intervention had no effect on targeted 181 
antipsychotic prescribing. The post intervention period is also relatively short, particularly for the 2014/15 182 
intervention.  Finally, we cannot exclude the possibility that the observed associations are due to some other 183 
intervention happening at the same time, and the difference in NSAID and antipsychotic outcomes might also be due 184 
to changing pressures and priorities in primary care. However, there was no other intervention in Forth Valley during 185 
the period examined, and the comparison with GGC provides some reassurance that the Forth Valley intervention 186 
caused the observed changes in prescribing.  187 
Comparison with existing literature 188 
The impact of this real-world intervention on the high risk prescribing of NSAIDs at one year is similar to that 189 
observed in the DQIP trial of a more intensive complex intervention.12 DQIP reduced triple whammy, NSAIDs in older 190 
people, and NSAIDs with OAC by 23%, 56% and 69% respectively at the end of the 12 month intervention, compared 191 
to 55%, 70% and 55% in NHS Forth Valley (although the measures used in the two studies are not identical in 192 
design). The effect size is also similar in magnitude to those observed in the PINCER trial for a different NSAID 193 
measure (NSAIDs prescribed to people with a history of peptic ulcer).11 Like PINCER (but unlike DQIP), there was 194 
evidence of some waning of effect once the intervention ceased, although the impact at 12 months after the end if 195 
the intervention remained similar in magnitude to DQIP. Changes in NSAID prescribing were substantially larger than 196 
those observed in the simpler EFIPPS feedback intervention and it is notable that like this analysis, there was no 197 
evidence that the EFIPPS intervention reduced antipsychotic prescribing in older people.13  198 
Implications for research and/or practice 199 
Whether organisational interventions shown to be effective in phase 3 trials will be effective in real-world system-200 
wide implementation is often uncertain, since trials are usually carried out by volunteers and often have higher 201 
intensity of intervention supported by research funding.10, 14  This study shows that a phase 4 intervention reduced 202 
high-risk primary care prescribing of NSAIDS to a similar degree as the two previous large phase 3 trials of similar 203 
complex interventions in this field.  Consistent with the EFIPPS study,13 this analysis shows that impact may at least 204 
partly depend on the prescribing targeted. In Forth Valley, the same intervention was highly effective at reducing 205 
high-risk NSAID prescribing but ineffective at reducing antipsychotic prescribing in older people. Neither this study 206 
nor the EFIPPS trial can examine why this should be, but one possible explanation is that NSAID prescribing is largely 207 
initiated and managed by GPs,20 whereas antipsychotic prescribing is commonly initiated by specialists plausibly 208 
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reducing GP ownership of it even when they are responsible for prescribing antipsychotics longer-term. GPs also 209 
report that they continue antipsychotic prescribing in older people because of a sense of futility and concerns about 210 
harm if prescribing is stopped.21 There is therefore unlikely to be a single ‘magic bullet’ intervention that will be 211 
effective for all high-risk prescribing.  212 
Conclusion 213 
Overall, the findings suggest that a blends of the intervention components used in trials (education, feedback 214 
financial incentives) tailored to a local context are likely to be effective in system-wide implementation.  The partial 215 
waning of effect in the year after the intervention ceased highlights that trials should ideally follow-up patients 216 
beyond the duration of the intervention, and that at least some interventions may need to be repeated to be 217 
sustainable. However, the lack of impact on antipsychotic prescribing in older people in this study and in the EFIPPS 218 
trial 13 indicates the need for more research into how best to reduce this prescribing. Although randomised trials will 219 
be helpful in addressing many of these uncertainties, further rigorous evaluations of phase 4 system-wide 220 
implementations would be of great value. The growth of electronic prescribing makes interventions of this kind 221 
increasingly feasible internationally, and the time is ripe for wider implementation to improve prescribing safety.  222 
 223 
  224 
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Box 1: Description of the NHS Forth Valley intervention to improve primary care prescribing safety 238 
Context of the intervention  
From April 2010 to March 2017 NHS Forth Valley contracted an enhanced service with GP practices 
called Whole System Working (WSW).  WSW in the financial periods of 2013/14 and 2014/15 
included an intervention to improve primary care prescribing safety focused on reducing the use of 
unsafe drug combinations, alongside other activities to improve patient safety, to improve 
communication between practices, hospital consultants and out-of-hours services, and increasing 
engagement with locality improvement activity. In each financial year, for completing all WSW 
work, practices were paid 80p per registered patient per annum (approximately £4000 for an 
average sized practice of 5000 patients). 
 
Specifics of the primary care prescribing safety intervention 
Targeted high-risk prescribing in 2013/2014:  
Patients aged ≥  65 years prescribed the ‘triple whammy‘ combination (NSAID +ACE/ARB + diuretic) 
Patients aged ≥ 65 years prescribed an NSAID without gastroprotection 
Current anticoagulant user prescribed an NSAID without gastroprotection 
 
Targeted high-risk prescribing in 2014/2015:  
Patients aged ≥  75 years prescribed an oral antipsychotic 
 
Educational workshop 
A brief educational intervention focusing on NSAID risks (quarter 2 2013) and antipsychotic risks in 
older people (quarter 2 2014) lasting approximately 45 minutes was delivered each year in June 
during a 2.5 hours long educational session on Patient Safety in Primary Care that the majority of 
GPs attended. This included comparative data on practice rates for that year’s measures, and what 
was expected of practices.      
 
Feedback and written educational material 
During each year around the same time as the educational workshop each practice was provided 
written educational material summarising the educational outreach workshop information 
accompanied by a single round of feedback showing practice rates of targeted high-risk prescribing 
compared to the average for the Health Board and practices’ ranking within the Health Board.  The 
same written material and feedback were given directly to all participants at the educational 
workshop.  
 
Financial incentive 
Within each year practices qualified for the WSW payment only when they provided evidence of 
completing all WSW elements.  The evidence required for the high-risk prescribing component was 
simply to report to the Health Board the number of patients triggering the measures at baseline and 
6 months later, rather than provide evidence change in high-risk prescribing rates. 
 
Support for identification of patients to review 
In both years, practices identified patients for review using search tools supplied by the NHS Forth 
Valley to run in their own electronic medical record systems. Health Board employed pharmacists 
reviewed the output of these searches to produce a clean list of patients for GPs to focus on (for 
example, by checking that the patient had actually received the targeted drug combinations). GPs 
were asked to review identified patients’ records, and then take whatever action they judged 
appropriate (e.g. continuing, amending or stopping medication without further review; contacting 
the patient to discuss; etc.). There was no WSW requirement to report to the Health Board the 
actual action taken. 
 239 
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Table 1: Targeted prescribing and outcome measure definition  240 
Measure short 
name 
Measure definition (number of patients in 
Forth Valley immediately before the 
intervention started) 
Associated harm Forth Valley 
intervention period 
Prevalence of high-risk prescribing 
in Forth Valley immediately before 
the intervention started 
Rate per 1000 (95% CI) 
Triple whammy Patients aged ≥ 65 years (n=51,595) who are 
prescribed a diuretic and an ACE inhibitor or 
angiotensin receptor blocker and an NSAID 
(n=596) 
Acute kidney 
injury22, 23 
April 2013 to 
March 2014 
11.6 (10.7 to 12.6) b 
NSAIDs in older 
people 
Patients aged ≥ 65 years (n=51,595) who are 
prescribed an NSAID without gastroprotection 
(n=1,832) 
Gastro-intestinal 
bleeding24 
April 2013 to 
March 2014  35.5 (33.9 to 37.1)  b 
NSAIDs with OAC Patients prescribed an oral anticoagulant 
(OAC) (n=3,423) who are prescribed an NSAID 
without gastroprotection (n=23) 
Gastro-intestinal 
bleeding24 
April 2013 to 
March 2014  6.7 (4.5 to 10.0) c 
Antipsychotics in 
older people a 
Patients aged ≥ 75 years (n=22,980) who are 
prescribed an oral antipsychotic (n=512) 
Stroke and death25 April 2014 to 
March 2015  
22.3 (20.5 to 24.3 d 
a. As a proxy for older people with dementia 241 
b. Rate per 1,000 population aged 65+ 242 
c. Rate per 1,000 prescribed an oral anticoagulant 243 
d. Rate per 1,000 population aged 75+  244 
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Table 2: Forth Valley segmented regression analysis 245 
Prescribing Measures 
Baseline rate 
Patients 
prescribed per 
1,000 at risk 
(95% CI) 
Trend before 
the intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Immediate 
step-change in 
rate at the start 
of the 
intervention 
period (95% CI) 
Change in trend 
after the start 
of the 
intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Immediate 
step-change in 
rate at the end 
of the 
intervention 
period (95% CI) 
Change in trend 
after the end of 
the intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Absolute 
difference at the 
end of the 
intervention 
period, patients 
prescribed per 
1,000 at risk  
(95% CI) 
Absolute 
difference 12 
months after the  
end of the 
intervention 
period, patients 
prescribed per 
1,000 at risk  
(95% CI) 
2013-14 Outcome Measures from Whole System Working in NHS Forth Valley
Triple whammy -
patients aged 65+ years 
prescribed an NSAID and 
an ACE/ARB and a 
diuretica 
13.1 
(12.4 to 13.8) 
-0.2 
(-0.2 to -0.1) 
-0.5 
(-1.3 to 0.3) 
-1.2 
(-1.4 to -1.1) 
1.5 
(1.1 to 1.9) 
1.3 
(1.2 to 1.3) 
-5.5 
(-6.7 to -4.3) 
-4.0 
(-5.4 to -2.6) 
NSAIDs in older people - 
patients aged 65+ years 
prescribed an NSAID 
without 
gastroprotectiona 
44.1 
(42.9 to 45.4) 
-0.7 
(-0.9 to -0.6) 
-1.6 
(-3.8 to 0.6) 
-4.6 
(-4.95 to -4.3) 
7.4 
(6.2 to 8.5) 
5.2 
(4.9 to 5.6) 
-20.1 
(-23.0 to -17.1) 
-10.3 
(-13.9 to -6.8) 
NSAIDs with OAC - 
patients prescribed an 
oral anticoagulant and a 
NSAID without 
gastroprotectionb 
9.1 
(8.1 to 10.1) 
-0.2 
(-0.3 to -0.04) 
-2.0 
(-3.6 to -0.3) 
-0.3 
(-0.8 to 0.2) 
0.6 
(-0.8 to 2.0) 
0.6 
(0.1 to 1.1) 
-3.3 
(-4.9 to -1.6) 
-1.5 
(-3.5 to 0.6) 
2014-15 Outcome Measure from Whole System Working in NHS Forth Valley
Antipsychotics in older 
people - patients aged 
75+ prescribed an oral 
antipsychoticc 
19.6 
(18.7 to 20.5) 
0.1 
(-0.01 to 0.1) 
-0.1 
(-1.1 to 0.8) 
0.1 
(-0.1 to 0.3) 
-0.6 
(-1.4 to 0.2) 
0.3 
(0.1 to 0.6) 
0.2 
(-1.2 to 1.5) 
1.2 
(-0.5 to 2.9) 
a. Rate per 1,000 of the population aged 65+ 246 
b. Rate per 1,000 prescribed an oral anticoagulant 247 
c. Rate per 1,000 of the population aged 75+ 248 
249 
FV QI paper - 20161103(25) final 
 
Table 3: Relative effect size in changed rates of high risk prescribing in NHS Forth Valley and for the difference between NHS Forth Valley and NHS GGC 250 
Prescribing Measures 
NHS Forth Valley Difference between NHS Forth Valley and NHS GGC 
Relative difference (%) from 
predicted at the end of the 
intervention period (95% CI) 
Relative difference (%) from 
predicted 12 months after the 
end of the intervention period 
(95% CI) 
Relative difference (%)
compared to GGC at the end of 
the intervention period (95% 
CI) 
Relative difference (%)
compared to GGC 12 months 
after the end of the 
intervention period (95% CI) 
2013-14 Outcome Measures from Whole System Working in NHS Forth Valley 
Triple whammy -patients 
aged 65+ years prescribed 
an NSAID and an ACE/ARB 
and a diuretica 
-55.4 (-67.2 to -43.6) -42.7 (-58.0 to -27.4) -34.3 (-42.3 to -26.4) -25.7 (-36.3 to -15.2) 
NSAIDs in older people - 
patients aged 65+ years 
prescribed an NSAID 
without gastroprotectiona 
-69.9 (-80.2 to -59.6) -40.1 (-53.8 to -26.4) -59.4 (-66.3 to -52.5) -28.6 (-38.3 to -18.8) 
NSAIDs with OAC - 
patients prescribed an oral 
anticoagulant and a NSAID 
without gastroprotectionb 
-55.1 (-83.2 to -27.0) -27.6 (-66.7 to 11.4) -85.0 (-100 to -45.5) -69.0 (-100 to -27.2) 
2014-15 Outcome Measure from Whole System Working in NHS Forth Valley 
Antipsychotics in older 
people - patients aged 75+ 
prescribed an oral 
antipsychoticc 
0.8 (-5.7 to 7.2) 5.6 (-2.3 to 13.5) -11.3 (-18.9 to -3.6) -2.0 (-10.4 to 6.5) 
a. Rate per 1,000 of the population aged 65+ 251 
b. Rate per 1,000 prescribed an oral anticoagulant 252 
c. Rate per 1,000 of the population aged 75+ 253 
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APPENDIX A: Primary and secondary analysis estimates of absolute and relative change, and detailed results of the 
difference in differences analysis 
 
Figure A1 illustrates the primary analysis estimating the intervention effect size (δ1) at the end of the intervention 
period. This is the difference between the rate predicted at the end of the intervention period if the pre-intervention 
trends continued unchanged (ܻ10), and the rate predicted at the end of intervention period using the intervention 
period observed values (ܻ11).   
 
Figure A2 shows the trends in both Health Boards for the same measure. The difference in differences estimate (δ3) is 
the difference between the change in Forth Valley (δ1) and the change in GGC (δ2). In practice, it is more 
straightforward to fit a model to the single line that is the difference between Forth Valley and GGC at every time 
point (figure A3). The difference in differences analysis is then the same as the primary analysis in figure A1, with the 
impact at the end of the intervention period being the difference in differences estimate (δ3) described above.  
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Table A1: Differences in high risk prescribing between NHS Forth Valley and NHS GGC1 
Prescribing Measures 
Baseline rate 
Patients 
prescribed per 
1,000 at risk 
(95% CI) 
Trend before 
the intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Immediate 
step-change in 
rate at the start 
of the 
intervention 
period (95% CI) 
Change in trend 
after the start 
of the 
intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Immediate 
step-change in 
rate at the end 
of the 
intervention 
period (95% CI) 
Change in trend 
after the end of 
the intervention 
period, change 
in rate per 
quarter (95% 
CI) 
Absolute 
difference at the 
end of the 
intervention 
period, patients 
prescribed per 
1,000 at risk  
(95% CI) 
Absolute 
difference 12 
months after the  
end of the 
intervention 
period, patients 
prescribed per 
1,000 at risk  
(95% CI) 
2013-14 Outcome Measures from Whole System Working in NHS Forth Valley
Triple whammy -
patients aged 65+ years 
prescribed an NSAID and 
an ACE/ARB and a 
diuretica 
-2.7 
(-3.2 to -2.3) 
0.04 
(-0.02 to 0.1) 
-0.5 
(-1.1 to 0.1) 
-0.7 
(-0.8 to -0.7) 
0.6 
(0.1 to 1.1) 
0.8 
(0.7 to 0.95) 
-3.4 
(-4.2 to -2.6) 
-2.4 
(-3.4 to -1.4) 
NSAIDs in older people - 
patients aged 65+ years 
prescribed an NSAID 
without 
gastroprotectiona 
3.6 
(2.6 to 4.6) 
-0.3 
(-0.4 to -0.1) 
-2.2 
(-3.8 to -0.7) 
-3.7 
(-3.8 to -3.6) 
5.7 
(5.0 to 6.4) 
4.7 
(4.5 to 4.9) 
-17.1 
(-19.1 to -15.1) 
-7.4 
(-9.9 to -4.9) 
NSAIDs with OAC - 
patients prescribed an 
oral anticoagulant and a 
NSAID without 
gastroprotectionb 
-1.0 
(-2.3 to 0.2) 
0.1 
(-0.04 to 0.2) 
-2.1 
(-3.6 to -0.6) 
-0.7 
(-1.3 to -0.2) 
1.2 
(-1.0 to 3.5) 
0.8 
(0.1 to 1.4) 
-5.0 
(-7.4 to -2.7) 
-3.7 
(-5.9 to -1.4) 
2014-15 Outcome Measure from Whole System Working in NHS Forth Valley
Antipsychotics in older 
people - patients aged 
75+ prescribed an oral 
antipsychoticc 
-8.1 
(-9.2 to -7.0) 
0.3 
(0.2 to 0.4) 
-1.9 
(-3.1 to -0.7) 
-0.1 
(-0.4 to 0.2) 
-0.2 
(-1.2 to 0.7) 
0.7 
(0.4 to 0.9) 
-2.4 
(-4.0 to -0.8) 
-0.4 
(-2.3 to 1.4) 
a. Rate per 1,000 of the population aged 65+ 
b. Rate per 1,000 prescribed an oral anticoagulant 
c. Rate per 1,000 of the population aged 75+ 
                                                            
1 For each time point value the difference between Forth Valley and GGC is calculated.  For triple whammy the rate of prescribing at baseline in Forth Valley is 2.7 lower than GGC, there is no different in the trend prior to 
the intervention period (both are downward trends), and there is no difference in the change of rate at the start of the intervention period.  The trend following the start of the intervention period declines more rapidly in 
Forth Valley than in GGC (-0.7 per quarter) and at the end of the intervention period the rate in FV increases compared to GGC (0.6).  Following the end of the intervention period the prescribing trend increases more 
rapidly in Forth Valley than in GGC (0.8 per quarter).  At the end of the intervention period and 12 months later the rate of prescribing is lower in Forth Valley compared to GGC (-3.4) and (-2.4) respectively. 
